Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 861M 758M 699M 654M 1.23B 81.17B 1.25B 8.4B 3.26B 40.04B 3.23B 3.16B 139B P/E 2026 *
14.6x
P/E 2027 * 11.1x
Enterprise Value 1.17B 1.03B 952M 890M 1.67B 110B 1.7B 11.44B 4.43B 54.49B 4.4B 4.3B 190B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.31x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day+7.63%
1 week+7.70%
Current month+10.90%
1 month+11.14%
3 months+8.71%
6 months-22.03%
Current year-21.94%
1 week 18.22
Extreme 18.22
20.93
1 month 17.73
Extreme 17.73
20.93
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-02Tax

Director

-769 0.0017%
06-01Free

Director

25,508 0.0579%
06-01Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
+7.65%+7.70%-14.95%-62.20% 861M
+0.85%-0.07%+42.82%+145.44% 987B
+0.94%+2.60%+57.89%+46.85% 576B
+0.05%+6.34%+26.79%+74.33% 415B
+3.61%-1.30%+22.76%+15.66% 320B
+2.35%+3.25%+34.63%+23.18% 278B
+0.75%+2.76%+30.31%+39.83% 279B
+1.23%+9.11%-31.23%-42.04% 208B
+1.35%+3.20%+27.07%+56.90% 187B
+0.14%+0.19%+17.24%+64.17% 155B
Average +1.90%+0.66%+21.33%+36.21% 340.61B
Weighted average by Cap. +1.15%+0.73%+33.28%+69.23%

Financials

2026 *2027 *
Net sales 747M 657M 606M 567M 1.06B 70.39B 1.08B 7.29B 2.82B 34.72B 2.8B 2.74B 121B 788M 694M 640M 599M 1.12B 74.32B 1.14B 7.69B 2.98B 36.66B 2.96B 2.9B 128B
Net income 64M 56.35M 51.97M 48.61M 91.07M 6.03B 92.77M 625M 242M 2.98B 240M 235M 10.35B 84M 73.95M 68.21M 63.8M 120M 7.92B 122M 820M 318M 3.91B 315M 309M 13.59B
Net Debt 311M 274M 252M 236M 442M 29.29B 450M 3.03B 1.17B 14.45B 1.17B 1.14B 50.27B 173M 153M 141M 132M 247M 16.35B 251M 1.69B 656M 8.06B 651M 637M 28.05B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
24/06/26 $20.91 +7.07% 409,162
23/06/26 $19.53 +6.55% 660,872
22/06/26 $18.33 -2.55% 767,439
18/06/26 $18.81 -3.09% 1,327,603
17/06/26 $19.41 -2.76% 1,008,517
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
19.53USD
Average target price
22.83USD
Spread / Average Target
+16.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!